Questcor plummets after Aetna slashes insurance coverage for most Acthar uses
This article was originally published in Scrip
Executive Summary
Questcor Pharmaceuticals' stock price was cut nearly in half - falling 47.8% from $50.52 per share on 18 September to $26.35 at market close on 19 September - in response to US health insurance company Aetna's decision to drop coverage for all but one of the 19 approved indications for HP Acthar gel (repository corticotropin injection).